Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Aeras | OTHER |
This observer blind study will assess the safety and immunogenicity of GSK Biologicals' investigational 692342 vaccine administered at 0, 1 month to healthy adolescents living in a TB-endemic region.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Group A | Experimental |
| |
| Group B | Placebo Comparator |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| GSK's investigational vaccine 692342 | Biological | Intramuscular injection, 2 doses |
| |
| Measure | Description | Time Frame |
|---|---|---|
| Number of Subjects With Solicited Local Symptoms | Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade. Grade 3 pain = pain that prevented normal activity. Grade 3 redness/swelling = redness/swelling spreading beyond 50 millimeters (mm) of injection site. Relationship analysis was not performed. | During the 7-day (Days 0-6) post-vaccination period following each dose and across doses |
| Number of Subjects With Solicited General Symptoms | Assessed solicited general symptoms were fatigue, temperature [defined as axillary temperature equal to or above 37.5 degrees Celsius (°C)], gastrointestinal symptoms (gastro) [nausea, vomiting, diarrhoea and/or abdominal pain], headache, malaise and myalgia. Any = occurrence of the symptom regardless of intensity grade. Grade 3 symptom = symptom that prevented normal activity. Grade 3 fever = fever ≥ 39.5 °C. Related = symptom assessed by the investigator as related to the vaccination. | During the 7-day (Days 0-6) post-vaccination period following each dose and across doses |
| Number of Subjects With Unsolicited Adverse Events (AEs) | An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset out-side the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. Grade 3 AE = an AE which prevented normal, everyday activities. Related = AE assessed by the investigator as related to the vaccination. | During the 30-day (Days 0-29) post-vaccination period |
| Number of Subjects With Serious Adverse Events (SAEs) | Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity. |
| Measure | Description | Time Frame |
|---|---|---|
| Frequency of Mycobacterium Tuberculosis Fusion Protein (M72) Specific Cluster of Differentiation 4/8 (CD4/8+) T Cells Expressing at Least Two Different Cytokines | Among cytokines expressed were interleukin-2 [IL-2], interferon-gamma [IFN-γ], tumour necrosis factor-alpha [TNF-α] and cluster of differentiation 40-ligand [CD40-L]. Analysis of cytokines expression was done by means of in vitro flow cytometry, using intracellular cytokine staining (ICS). |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| GSK Clinical Trials | GlaxoSmithKline | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| GSK Investigational Site | Worcester | Western Province | 6850 | South Africa |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 26072017 | Derived | Penn-Nicholson A, Geldenhuys H, Burny W, van der Most R, Day CL, Jongert E, Moris P, Hatherill M, Ofori-Anyinam O, Hanekom W; Vaccine Study Team; Bollaerts A, Demoitie MA, Kany Luabeya AK, De Ruymaeker E, Tameris M, Lapierre D, Scriba TJ. Safety and immunogenicity of candidate vaccine M72/AS01E in adolescents in a TB endemic setting. Vaccine. 2015 Jul 31;33(32):4025-34. doi: 10.1016/j.vaccine.2015.05.088. Epub 2015 Jun 10. |
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | GSK692342 Group | Healthy subjects between and including 13 to 17 years of age at the time of first vaccination, who received 2 doses of the study vaccine at Day 0 and Day 30, in the arm's deltoid region. |
| FG001 | Placebo Group | Healthy subjects between and including 13 to 17 years of age at the time of first vaccination, who received 2 doses of physiological saline at Day 0 and Day 30, in the arm's deltoid region. |
| Title | Milestones | Reasons Not Completed | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Study |
|
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | GSK692342 Group | Healthy subjects between and including 13 to 17 years of age at the time of first vaccination, who received 2 doses of the study vaccine at Day 0 and Day 30, in the arm's deltoid region. |
| BG001 | Placebo Group |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes |
|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | Mean |
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Number of Subjects With Solicited Local Symptoms | Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade. Grade 3 pain = pain that prevented normal activity. Grade 3 redness/swelling = redness/swelling spreading beyond 50 millimeters (mm) of injection site. Relationship analysis was not performed. | The analysis was performed on the Total Vaccinated cohort, which included all vaccinated subjects for whom data were available. | Posted | Number | Subjects | During the 7-day (Days 0-6) post-vaccination period following each dose and across doses |
|
Solicited local/general symptoms during the 7-day post vaccination period (Days 0-6); AEs during the 30-day post vaccination period (Days 0-29), SAEs up to Day 210
Not provided
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | GSK692342 Group | Healthy subjects between and including 13 to 17 years of age at the time of first vaccination, who received 2 doses of the study vaccine at Day 0 and Day 30, in the arm's deltoid region. |
Not provided
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Pain | General disorders | MedDRA | Systematic Assessment |
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| GSK Response Center | GlaxoSmithKline | 866-435-7343 |
Not provided
| ID | Term |
|---|---|
| D014376 | Tuberculosis |
| ID | Term |
|---|---|
| D009164 | Mycobacterium Infections |
| D000193 | Actinomycetales Infections |
| D016908 | Gram-Positive Bacterial Infections |
| D001424 | Bacterial Infections |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Placebo |
| Biological |
Intramuscular injection, 2 doses |
|
| During the entire study period (from Day 0 up to Day 210) |
| Number of Subjects With Normal Biochemical and Haematological Levels | Among biochemical and haematological parameters assessed were alanine aminotransferase [ALT], aspartate aminotransferase [AST], creatinine [CREA], haemoglobin [Hgb]. Levels of haematological/biochemical parameters assessed in terms of normal laboratory values were - normal, below and above. | At Day 0, 7, 30, 37 and 60 |
| Number of Subjects With Normal Haematological Levels | Among haematological parameters assessed were platelets [PLA], red blood cells [RBC] and white blood cells [WBC]. Levels of haematological parameters assessed in terms of normal laboratory values were - normal, below and above. | At Day 0, 7, 30, 37 and 60 |
| Number of Subjects With Biochemical and Haematological Above Normal Levels | Among biochemical and haematological parameters assessed were alanine aminotransferase [ALT], aspartate aminotransferase [AST], creatinine [CREA], haemoglobin [Hgb]. Levels of haematological/biochemical parameters assessed in terms of normal laboratory values were - normal, below and above. | At Day 0, 7, 30, 37 and 60 |
| Number of Subjects With Haematological Levels Above Normal | Among haematological parameters assessed were platelets [PLA], red blood cells [RBC] and white blood cells [WBC]. Levels of haematological parameters assessed in terms of normal laboratory values were - normal, below and above. | At Day 0, 7, 30, 37 and 60 |
| Number of Subjects With Biochemical and Haematological Below Normal Levels | Among biochemical and haematological parameters assessed were alanine aminotransferase [ALT], aspartate aminotransferase [AST], creatinine [CREA], haemoglobin [Hgb]. Levels of haematological/biochemical parameters assessed in terms of normal laboratory values were - normal, below and above. | At Day 0, 7, 30, 37 and 60 |
| Number of Subjects With Haematological Levels Below Normal | Among haematological parameters assessed were platelets [PLA], red blood cells [RBC] and white blood cells [WBC]. Levels of haematological parameters assessed in terms of normal laboratory values were - normal, below and above. | At Day 0, 7, 30, 37 and 60 |
| At Day 0, 7, 30, 37, 60 and 210 |
| Frequency of M72 Specific CD4+ T Cells Expressing Any Combination of Cytokines | Among cytokines expressed were interleukin-2 [IL-2], interferon-gamma [IFN-γ], tumour necrosis factor-alpha [TNF-α] and cluster of differentiation 40-ligand [CD40-L], after background reduction stimulated by M72. Analysis of cytokines expression was done by means of in vitro flow cytometry, using intracellular cytokine staining (ICS). | At Day 0, 7, 30, 37, 60 and 210 |
| Frequency of M72 Specific CD8+ T Cells Expressing Any Combination of Cytokines | Among cytokines expressed were interleukin-2 [IL-2], interferon-gamma [IFN-γ], tumour necrosis factor-alpha [TNF-α] and cluster of differentiation 40-ligand [CD40-L], after background reduction stimulated by M72. Analysis of cytokines expression was done by means of in vitro flow cytometry, using intracellular cytokine staining (ICS). | At Day 0, 7, 30, 37, 60 and 210 |
| Anti-M72 Specific Antibody Concentrations | Antibody concentrations given in Enzyme-Linked Immunosorbent Assay (ELISA) units per millilitre (EL.U/mL) were expressed as Geometric Mean Concentrations (GMCs). | At Day 0, 30, 60 and 210 |
Healthy subjects between and including 13 to 17 years of age at the time of first vaccination, who received 2 doses of physiological saline at Day 0 and Day 30, in the arm's deltoid region.
| BG002 | Total | Total of all reporting groups |
| Years |
|
| Sex: Female, Male | Count of Participants | Participants |
|
| OG001 | Placebo Group | Healthy subjects between and including 13 to 17 years of age at the time of first vaccination, who received 2 doses of physiological saline at Day 0 and Day 30, in the arm's deltoid region. |
|
|
| Primary | Number of Subjects With Solicited General Symptoms | Assessed solicited general symptoms were fatigue, temperature [defined as axillary temperature equal to or above 37.5 degrees Celsius (°C)], gastrointestinal symptoms (gastro) [nausea, vomiting, diarrhoea and/or abdominal pain], headache, malaise and myalgia. Any = occurrence of the symptom regardless of intensity grade. Grade 3 symptom = symptom that prevented normal activity. Grade 3 fever = fever ≥ 39.5 °C. Related = symptom assessed by the investigator as related to the vaccination. | The analysis was performed on the Total Vaccinated cohort, which included all vaccinated subjects for whom data were available. | Posted | Number | Subjects | During the 7-day (Days 0-6) post-vaccination period following each dose and across doses |
|
|
|
| Primary | Number of Subjects With Unsolicited Adverse Events (AEs) | An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset out-side the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. Grade 3 AE = an AE which prevented normal, everyday activities. Related = AE assessed by the investigator as related to the vaccination. | The analysis was performed on the Total Vaccinated cohort, which included all vaccinated subjects for whom data were available. | Posted | Number | Subjects | During the 30-day (Days 0-29) post-vaccination period |
|
|
|
| Primary | Number of Subjects With Serious Adverse Events (SAEs) | Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity. | The analysis was performed on the Total Vaccinated cohort, which included all vaccinated subjects for whom data were available. | Posted | Number | Subjects | During the entire study period (from Day 0 up to Day 210) |
|
|
|
| Primary | Number of Subjects With Normal Biochemical and Haematological Levels | Among biochemical and haematological parameters assessed were alanine aminotransferase [ALT], aspartate aminotransferase [AST], creatinine [CREA], haemoglobin [Hgb]. Levels of haematological/biochemical parameters assessed in terms of normal laboratory values were - normal, below and above. | The analysis was performedon the Total Vaccinated cohort, which included all vaccinated subjects for whom data were available. | Posted | Number | Subjects | At Day 0, 7, 30, 37 and 60 |
|
|
|
| Primary | Number of Subjects With Normal Haematological Levels | Among haematological parameters assessed were platelets [PLA], red blood cells [RBC] and white blood cells [WBC]. Levels of haematological parameters assessed in terms of normal laboratory values were - normal, below and above. | The analysis was performed on the Total Vaccinated cohort, which included all vaccinated subjects for whom data were available. | Posted | Number | Subjects | At Day 0, 7, 30, 37 and 60 |
|
|
|
| Primary | Number of Subjects With Biochemical and Haematological Above Normal Levels | Among biochemical and haematological parameters assessed were alanine aminotransferase [ALT], aspartate aminotransferase [AST], creatinine [CREA], haemoglobin [Hgb]. Levels of haematological/biochemical parameters assessed in terms of normal laboratory values were - normal, below and above. | The analysis was performed on the Total Vaccinated cohort, which included all vaccinated subjects for whom data were available. | Posted | Number | Subjects | At Day 0, 7, 30, 37 and 60 |
|
|
|
| Primary | Number of Subjects With Haematological Levels Above Normal | Among haematological parameters assessed were platelets [PLA], red blood cells [RBC] and white blood cells [WBC]. Levels of haematological parameters assessed in terms of normal laboratory values were - normal, below and above. | The analysis was performed on the Total Vaccinated cohort, which included all vaccinated subjects for whom data were available. | Posted | Number | Subjects | At Day 0, 7, 30, 37 and 60 |
|
|
|
| Primary | Number of Subjects With Biochemical and Haematological Below Normal Levels | Among biochemical and haematological parameters assessed were alanine aminotransferase [ALT], aspartate aminotransferase [AST], creatinine [CREA], haemoglobin [Hgb]. Levels of haematological/biochemical parameters assessed in terms of normal laboratory values were - normal, below and above. | The analysis was performed on the Total Vaccinated cohort, which included all vaccinated subjects for whom data were available. | Posted | Number | Subjects | At Day 0, 7, 30, 37 and 60 |
|
|
|
| Primary | Number of Subjects With Haematological Levels Below Normal | Among haematological parameters assessed were platelets [PLA], red blood cells [RBC] and white blood cells [WBC]. Levels of haematological parameters assessed in terms of normal laboratory values were - normal, below and above. | The analysis was performed on the Total Vaccinated cohort, which included all vaccinated subjects for whom data were available. | Posted | Number | Subjects | At Day 0, 7, 30, 37 and 60 |
|
|
|
| Secondary | Frequency of Mycobacterium Tuberculosis Fusion Protein (M72) Specific Cluster of Differentiation 4/8 (CD4/8+) T Cells Expressing at Least Two Different Cytokines | Among cytokines expressed were interleukin-2 [IL-2], interferon-gamma [IFN-γ], tumour necrosis factor-alpha [TNF-α] and cluster of differentiation 40-ligand [CD40-L]. Analysis of cytokines expression was done by means of in vitro flow cytometry, using intracellular cytokine staining (ICS). | The analysis was performed on the According-to-Protocol (ATP) cohort for immunogenicity, which included all evaluable subjects who had received at least one dose of study vaccine/placebo according to their random assignment, for whom data concerning immunogenicity outcome measures were available. | Posted | Median | Inter-Quartile Range | T cells/million cells | At Day 0, 7, 30, 37, 60 and 210 |
|
|
|
| Secondary | Frequency of M72 Specific CD4+ T Cells Expressing Any Combination of Cytokines | Among cytokines expressed were interleukin-2 [IL-2], interferon-gamma [IFN-γ], tumour necrosis factor-alpha [TNF-α] and cluster of differentiation 40-ligand [CD40-L], after background reduction stimulated by M72. Analysis of cytokines expression was done by means of in vitro flow cytometry, using intracellular cytokine staining (ICS). | The analysis was performed on the ATP cohort for immunogenicity, which included all evaluable subjects who had received at least one dose of study vaccine/placebo according to their random assignment, for whom data concerning immunogenicity outcome measures were available. | Posted | Median | Inter-Quartile Range | T cells/million cells | At Day 0, 7, 30, 37, 60 and 210 |
|
|
|
| Secondary | Frequency of M72 Specific CD4+ T Cells Expressing Any Combination of Cytokines | Among cytokines expressed were interleukin-2 [IL-2], interferon-gamma [IFN-γ], tumour necrosis factor-alpha [TNF-α] and cluster of differentiation 40-ligand [CD40-L], after background reduction stimulated by M72. Analysis of cytokines expression was done by means of in vitro flow cytometry, using intracellular cytokine staining (ICS). | The analysis was performed on the ATP cohort for immunogenicity, which included all evaluable subjects who had received at least one dose of study vaccine/placebo according to their random assignment, for whom data concerning immunogenicity outcome measures were available. | Posted | Median | Inter-Quartile Range | T cells/million cells | At Day 0, 7, 30, 37, 60 and 210 |
|
|
|
| Secondary | Frequency of M72 Specific CD8+ T Cells Expressing Any Combination of Cytokines | Among cytokines expressed were interleukin-2 [IL-2], interferon-gamma [IFN-γ], tumour necrosis factor-alpha [TNF-α] and cluster of differentiation 40-ligand [CD40-L], after background reduction stimulated by M72. Analysis of cytokines expression was done by means of in vitro flow cytometry, using intracellular cytokine staining (ICS). | The analysis was performed on the ATP cohort for immunogenicity, which included all evaluable subjects who had received at least one dose of study vaccine/placebo according to their random assignment, for whom data concerning immunogenicity outcome measures were available. | Posted | Median | Inter-Quartile Range | T cells/million cells | At Day 0, 7, 30, 37, 60 and 210 |
|
|
|
| Secondary | Frequency of M72 Specific CD8+ T Cells Expressing Any Combination of Cytokines | Among cytokines expressed were interleukin-2 [IL-2], interferon-gamma [IFN-γ], tumour necrosis factor-alpha [TNF-α] and cluster of differentiation 40-ligand [CD40-L], after background reduction stimulated by M72. Analysis of cytokines expression was done by means of in vitro flow cytometry, using intracellular cytokine staining (ICS). | The analysis was performed on the ATP cohort for immunogenicity, which included all evaluable subjects who had received at least one dose of study vaccine/placebo according to their random assignment, for whom data concerning immunogenicity outcome measures were available. | Posted | Median | Inter-Quartile Range | T cells/million cells | At Day 0, 7, 30, 37, 60 and 210 |
|
|
|
| Secondary | Anti-M72 Specific Antibody Concentrations | Antibody concentrations given in Enzyme-Linked Immunosorbent Assay (ELISA) units per millilitre (EL.U/mL) were expressed as Geometric Mean Concentrations (GMCs). | The analysis was performed on the ATP cohort for immunogenicity, which included all evaluable subjects who had received at least one dose of study vaccine/placebo according to their random assignment, for whom data concerning immunogenicity outcome measures were available. | Posted | Geometric Mean | 95% Confidence Interval | EL.U/mL | At Day 0, 30, 60 and 210 |
|
|
|
| 0 |
| 40 |
| 38 |
| 40 |
| EG001 | Placebo Group | Healthy subjects between and including 13 to 17 years of age at the time of first vaccination, who received 2 doses of physiological saline at Day 0 and Day 30, in the arm's deltoid region. | 0 | 20 | 15 | 20 |
| Redness (millimeters) | General disorders | MedDRA | Systematic Assessment |
|
| Swelling (millimeters) | General disorders | MedDRA | Systematic Assessment |
|
| Fatigue | General disorders | MedDRA | Systematic Assessment |
|
| Gastrointestinal | General disorders | MedDRA | Systematic Assessment |
|
| Headache | General disorders | MedDRA | Systematic Assessment |
|
| Malaise | General disorders | MedDRA | Systematic Assessment |
|
| Myalgia | General disorders | MedDRA | Systematic Assessment |
|
| Temperature/(Orally) (°C) | General disorders | MedDRA | Systematic Assessment |
|
| Diarrhoea | Gastrointestinal disorders | MedDRA | Systematic Assessment |
|
| Nasopharyngitis | Infections and infestations | MedDRA | Systematic Assessment |
|
| Joint injury | Injury, poisoning and procedural complications | MedDRA | Systematic Assessment |
|
| Joint sprain | Injury, poisoning and procedural complications | MedDRA | Systematic Assessment |
|
| Alanine aminotransferase increased | Investigations | MedDRA | Systematic Assessment |
|
| Haemoglobin decreased | Investigations | MedDRA | Systematic Assessment |
|
| White blood cell count decreased | Investigations | MedDRA | Systematic Assessment |
|
| Dizziness | Nervous system disorders | MedDRA | Systematic Assessment |
|
| Dysmenorrhoea | Reproductive system and breast disorders | MedDRA | Systematic Assessment |
|
GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.
| D001423 | Bacterial Infections and Mycoses |
| D007239 | Infections |
| Grade 3 Fatigue, Dose 1 [N=40;18] |
|
| Any Gastro, Dose 1 [N=40;18] |
|
| Related Gastro, Dose 1 [N=40;18] |
|
| Grade 3 Gastro, Dose 1 [N=40;18] |
|
| Any Headache, Dose 1 [N=40;18] |
|
| Related Headache, Dose 1 [N=40;18] |
|
| Grade 3 Headache, Dose 1 [N=40;18] |
|
| Any Malaise, Dose 1 [N=40;18] |
|
| Related Malaise, Dose 1 [N=40;18] |
|
| Grade 3 Malaise, Dose 1 [N=40;18] |
|
| Any Myalgia, Dose 1 [N=40;18] |
|
| Related Myalgia, Dose 1 [N=40;18] |
|
| Grade 3 Myalgia, Dose 1 [N=40;18] |
|
| Any Temperature, Dose 1 [N=40;18] |
|
| Related Temperature, Dose 1 [N=40;18] |
|
| Grade 3 Temperature, Dose 1 [N=40;18] |
|
| Any Fatigue, Dose 2 [N=40;20] |
|
| Related Fatigue, Dose 2 [N=40;20] |
|
| Grade 3 Fatigue, Dose 2 [N=40;20] |
|
| Any Gastro, Dose 2 [N=40;20] |
|
| Related Gastro, Dose 2 [N=40;20] |
|
| Grade 3 Gastro, Dose 2 [N=40;20] |
|
| Any Headache, Dose 2 [N=40;20] |
|
| Related Headache, Dose 2 [N=40;20] |
|
| Grade 3 Headache, Dose 2 [N=40;20] |
|
| Any Malaise, Dose 2 [N=40;20] |
|
| Related Malaise, Dose 2 [N=40;20] |
|
| Grade 3 Malaise, Dose 2 [N=40;20] |
|
| Any Myalgia, Dose 2 [N=40;20] |
|
| Related Myalgia, Dose 2 [N=40;20] |
|
| Grade 3 Myalgia, Dose 2 [N=40;20] |
|
| Any Temperature, Dose 2 [N=40;20] |
|
| Related Temperature, Dose 2 [N=40;20] |
|
| Grade 3 Temperature, Dose 2 [N=40;20] |
|
| Any Fatigue, Across [N=40;20] |
|
| Related Fatigue, Across [N=40;20] |
|
| Grade 3 Fatigue, Across [N=40;20] |
|
| Any Gastro, Across [N=40;20] |
|
| Related Gastro, Across [N=40;20] |
|
| Grade 3 Gastro, Across [N=40;20] |
|
| Any Headache, Across [N=40;20] |
|
| Related Headache, Across [N=40;20] |
|
| Grade 3 Headache, Across [N=40;20] |
|
| Any Malaise, Across [N=40;20] |
|
| Related Malaise, Across [N=40;20] |
|
| Grade 3 Malaise, Across [N=40;20] |
|
| Any Myalgia, Across [N=40;20] |
|
| Related Myalgia, Across [N=40;20] |
|
| Grade 3 Myalgia, Across [N=40;20] |
|
| Any Temperature, Across [N=40;20] |
|
| Related Temperature, Across [N=40;20] |
|
| Grade 3 Temperature, Across [N=40;20] |
|
| ALT, Day 30-normal |
|
| ALT, Day 37-normal |
|
| ALT, Day 60-normal |
|
| AST, Day 0-normal |
|
| AST, Day 7-normal |
|
| AST, Day 30-normal |
|
| AST, Day 37-normal |
|
| AST, Day 60-normal |
|
| CREA, Day 0-normal |
|
| CREA, Day 7-normal |
|
| CREA, Day 30-normal |
|
| CREA, Day 37-normal |
|
| CREA, Day 60-normal |
|
| Hgb, Day 0-normal |
|
| Hgb, Day 7-normal |
|
| Hgb, Day 30-normal |
|
| Hgb, Day 37-normal |
|
| Hgb, Day 60-normal |
|
| PLA, Day 30-normal |
|
| PLA, Day 37-normal |
|
| PLA, Day 60-normal |
|
| RBC, Day 0-normal |
|
| RBC, Day 7-normal |
|
| RBC, Day 30-normal |
|
| RBC, Day 37-normal |
|
| RBC, Day 60-normal |
|
| WBC, Day 0-normal |
|
| WBC, Day 7-normal |
|
| WBC, Day 30-normal |
|
| WBC, Day 37-normal |
|
| WBC, Day 60-normal |
|
| ALT, Day 30- above |
|
| ALT, Day 37- above |
|
| ALT, Day 60- above |
|
| AST, Day 0- above |
|
| AST, Day 7- above |
|
| AST, Day 30- above |
|
| AST, Day 37- above |
|
| AST, Day 60- above |
|
| CREA, Day 0- above |
|
| CREA, Day 7- above |
|
| CREA, Day 30- above |
|
| CREA, Day 37- above |
|
| CREA, Day 60- above |
|
| Hgb, Day 0- above |
|
| Hgb, Day 7- above |
|
| Hgb, Day 30- above |
|
| Hgb, Day 37- above |
|
| Hgb, Day 60- above |
|
| PLA, Day 30- above |
|
| PLA, Day 37- above |
|
| PLA, Day 60- above |
|
| RBC, Day 0- above |
|
| RBC, Day 7- above |
|
| RBC, Day 30- above |
|
| RBC, Day 37- above |
|
| RBC, Day 60- above |
|
| WBC, Day 0- above |
|
| WBC, Day 7- above |
|
| WBC, Day 30- above |
|
| WBC, Day 37- above |
|
| WBC, Day 60- above |
|
| ALT, Day 30-below |
|
| ALT, Day 37-below |
|
| ALT, Day 60-below |
|
| AST, Day 0-below |
|
| AST, Day 7-below |
|
| AST, Day 30-below |
|
| AST, Day 37- below |
|
| AST, Day 60- below |
|
| CREA, Day 0- below |
|
| CREA, Day 7- below |
|
| CREA, Day 30-below |
|
| CREA, Day 37-below |
|
| CREA, Day 60-below |
|
| Hgb, Day 0- below |
|
| Hgb, Day 7- below |
|
| Hgb, Day 30- below |
|
| Hgb, Day 37- below |
|
| Hgb, Day 60- below |
|
| PLA, Day 30-below |
|
| PLA, Day 37-below |
|
| PLA, Day 60-below |
|
| RBC, Day 0-below |
|
| RBC, Day 7-below |
|
| RBC, Day 30-below |
|
| RBC, Day 37-below |
|
| RBC, Day 60-below |
|
| WBC, Day 0-below |
|
| WBC, Day 7-below |
|
| WBC, Day 30-below |
|
| WBC, Day 37-below |
|
| WBC, Day 60-below |
|
| CD4-All Doubles, Day 30 [N=38;18] |
|
| CD4-All Doubles, Day 37 [N=37;19] |
|
| CD4-All Doubles, Day 60 [N=38;20] |
|
| CD4-All Doubles, Day 210 [N=36;20] |
|
| CD8-All Doubles, Day 0 [N=36;17] |
|
| CD8-All Doubles, Day 7 [N=32;15] |
|
| CD8-All Doubles, Day 30 [N=38;18] |
|
| CD8-All Doubles, Day 37 [N=37;19] |
|
| CD8-All Doubles, Day 60 [N=38;20] |
|
| CD8-All Doubles, Day 210 [N=36;20] |
|
| CD4.CD40L(+)+IL-2(-)+TNFα(-)+IFNγ(-)D30[N=39;20] |
|
| CD4.CD40L(+)+IL-2(-)+TNFα(-)+IFNγ(-)D37[N=39;20] |
|
| CD4.CD40L(+)+IL-2(-)+TNFα(-)+IFNγ(-)D60[N=38;20] |
|
| CD4.CD40L(+)+IL-2(-)+TNFα(-)+IFNγ(-)D210[N=37;20] |
|
| CD4.CD40L(-)+IL-2(+)+TNFα(-)+IFNγ(-)D0[N=38;19] |
|
| CD4.CD40L(-)+IL-2(+)+TNFα(-)+IFNγ(-)D7[N=36;15] |
|
| CD4.CD40L(-)+IL-2(+)+TNFα(-)+IFNγ(-)D30[N=39;20] |
|
| CD4.CD40L(-)+IL-2(+)+TNFα(-)+IFNγ(-)D37[N=39;20] |
|
| CD4.CD40L(-)+IL-2(+)+TNFα(-)+IFNγ(-)D60[N=38;20] |
|
| CD4.CD40L(-)+IL-2(+)+TNFα(-)+IFNγ(-)D210[N=37;20] |
|
| CD4.CD40L(-)+IL-2(-)+TNFα(+)+IFNγ(-)D0[N=38;19] |
|
| CD4.CD40L(-)+IL-2(-)+TNFα(+)+IFNγ(-)D7[N=36;15] |
|
| CD4.CD40L(-)+IL-2(-)+TNFα(+)+IFNγ(-)D30[N=39;20] |
|
| CD4.CD40L(-)+IL-2(-)+TNFα(+)+IFNγ(-)D37[N=39;20] |
|
| CD4.CD40L(-)+IL-2(-)+TNFα(+)+IFNγ(-)D60[N=38;20] |
|
| CD4.CD40L(-)+IL-2(-)+TNFα(+)+IFNγ(-)D210[N=37;20] |
|
| CD4.CD40L(-)+IL-2(-)+TNFα(-)+IFNγ(+)D0[N=38;19] |
|
| CD4.CD40L(-)+IL-2(-)+TNFα(-)+IFNγ(+)D7[N=36;15] |
|
| CD4.CD40L(-)+IL-2(-)+TNFα(-)+IFNγ(+)D30[N=39;20] |
|
| CD4.CD40L(-)+IL-2(-)+TNFα(-)+IFNγ(+)D37[N=39;20] |
|
| CD4.CD40L(-)+IL-2(-)+TNFα(-)+IFNγ(+)D60[N=38;20] |
|
| CD4.CD40L(-)+IL-2(-)+TNFα(-)+IFNγ(+)D210[N=37;20] |
|
| CD4.CD40L(+)+IL-2(+)+TNFα(-)+IFNγ(-)D0[N=38;19] |
|
| CD4.CD40(+)+IL-2(+)+TNFα(-)+IFNγ(-)D7[N=36;15] |
|
| CD4.CD40L(+)+IL-2(+)+TNFα(-)+IFNγ(-)D30[N=39;20] |
|
| CD4.CD40L(+)+IL-2(+)+TNFα(-)+IFNγ(-)D37[N=39;20] |
|
| CD4.CD40L(+)+IL-2(+)+TNFα(-)+IFNγ(-)D60[N=38;20] |
|
| CD4.CD40L(+)+IL-2(+)+TNFα(-)+IFNγ(-)D210[N=37;20] |
|
| CD4.CD40L(+)+IL-2(-)+TNFα(+)+IFNγ(-)D0[N=38;19] |
|
| CD4.CD40L(+)+IL-2(-)+TNFα(+)+IFNγ(-)D7[N=36;15] |
|
| CD4.CD40L(+)+IL-2(-)+TNFα(+)+IFNγ(-)D30[N=39;20] |
|
| CD4.CD40L(+)+IL-2(-)+TNFα(+)+IFNγ(-)D37[N=39;20] |
|
| CD4.CD40L(+)+IL-2(-)+TNFα(+)+IFNγ(-)D60[N=38;20] |
|
| CD4.CD40L(+)+IL-2(-)+TNFα(+)+IFNγ(-)D210[N=37;20] |
|
| CD4.CD40L(+)+IL-2(-)+TNFα(-)+IFNγ(+)D0[N=38;19] |
|
| CD4.CD40L(+)+IL-2(-)+TNFα(-)+IFNγ(+)D7[N=36;15] |
|
| CD4.CD40L(+)+IL-2(-)+TNFα(-)+IFNγ(+)D30[N=39;20] |
|
| CD4.CD40L(+)+IL-2(-)+TNFα(-)+IFNγ(+)D37[N=39;20] |
|
| CD4.CD40L(+)+IL-2(-)+TNFα(-)+IFNγ(+)D60[N=38;20] |
|
| CD4.CD40L(+)+IL-2(-)+TNFα(-)+IFNγ(+)D210[N=37;20] |
|
| CD4.CD40L(-)+IL-2(+)+TNFα(+)+IFNγ(-)D30[N=39;20] |
|
| CD4.CD40L(-)+IL-2(+)+TNFα(+)+IFNγ(-)D37[N=39;20] |
|
| CD4.CD40L(-)+IL-2(+)+TNFα(+)+IFNγ(-)D60[N=38;20] |
|
| CD4.CD40L(-)+IL-2(+)+TNFα(+)+IFNγ(-)D210[N=37;20] |
|
| CD4.CD40L(-)+IL-2(+)+TNFα(-)+IFNγ(+)D0[N=38;19] |
|
| CD4.CD40L(-)+IL-2(+)+TNFα(-)+IFNγ(+)D7[N=36;15] |
|
| CD4.CD40L(-)+IL-2(+)+TNFα(-)+IFNγ(+)D30[N=39;20] |
|
| CD4.CD40L(-)+IL-2(+)+TNFα(-)+IFNγ(+)D37[N=39;20] |
|
| CD4.CD40L(-)+IL-2(+)+TNFα(-)+IFNγ(+)D60[N=38;20] |
|
| CD4.CD40L(-)+IL-2(+)+TNFα(-)+IFNγ(+)D210[N=37;20] |
|
| CD4.CD40L(-)+IL-2(-)+TNFα(+)+IFNγ(+)D0[N=38;19] |
|
| CD4.CD40L(-)+IL-2(-)+TNFα(+)+IFNγ(+)D7[N=36;15] |
|
| CD4.CD40L(-)+IL-2(-)+TNFα(+)+IFNγ(+)D30[N=39;20] |
|
| CD4.CD40L(-)+IL-2(-)+TNFα(+)+IFNγ(+)D37[N=39;20] |
|
| CD4.CD40L(-)+IL-2(-)+TNFα(+)+IFNγ(+)D60[N=38;20] |
|
| CD4.CD40L(-)+IL-2(-)+TNFα(+)+IFNγ(+)D210[N=37;20] |
|
| CD4.CD40L(+)+IL-2(+)+TNFα(+)+IFNγ(-)D0[N=38;19] |
|
| CD4.CD40L(+)+IL-2(+)+TNFα(+)+IFNγ(-)D7[N=36;15] |
|
| CD4.CD40L(+)+IL-2(+)+TNFα(+)+IFNγ(-)D30[N=39;20] |
|
| CD4.CD40L(+)+IL-2(+)+TNFα(+)+IFNγ(-)D37[N=39;20] |
|
| CD4.CD40L(+)+IL-2(+)+TNFα(+)+IFNγ(-)D60[N=38;20] |
|
| CD4.CD40L(+)+IL-2(+)+TNFα(+)+IFNγ(-)D210[N=37;20] |
|
| CD4.CD40L(+)+IL-2(+)+TNFα(-)+IFNγ(+)D0[N=38;19] |
|
| CD4.CD40L(+)+IL-2(+)+TNFα(-)+IFNγ(+)D7[N=36;15] |
|
| CD4.CD40L(+)+IL-2(+)+TNFα(-)+IFNγ(+)D30[N=39;20] |
|
| CD4.CD40L(+)+IL-2(+)+TNFα(-)+IFNγ(+)D37[N=39;20] |
|
| CD4.CD40L(+)+IL-2(+)+TNFα(-)+IFNγ(+)D60[N=38;20] |
|
| CD4.CD40L(+)+IL-2(+)+TNFα(-)+IFNγ(+)D210[N=37;20] |
|
| CD4.CD40L(+)+IL-2(-)+TNFα(+)+IFNγ(+)D0[N=38;19] |
|
| CD4.CD40L(+)+IL-2(-)+TNFα(+)+IFNγ(+)D7[N=36;15] |
|
| CD4.CD40L(+)+IL-2(-)+TNFα(+)+IFNγ(+)D30[N=39;20] |
|
| CD4.CD40L(+)+IL-2(-)+TNFα(+)+IFNγ(+)D37[N=39;20] |
|
| CD4.CD40L(+)+IL-2(-)+TNFα(+)+IFNγ(+)D60[N=38;20] |
|
| CD4.CD40L(+)+IL-2(-)+TNFα(+)+IFNγ(+)D210[N=37;20] |
|
| CD4.CD40L(-)+IL-2(+)+TNFα(+)+IFNγ(+)D0[N=38;19] |
|
| CD4.CD40L(-)+IL-2(+)+TNFα(+)+IFNγ(+)D7[N=36;15] |
|
| CD4.CD40L(-)+IL-2(+)+TNFα(+)+IFNγ(+)D30[N=39;20] |
|
| CD4.CD40L(-)+IL-2(+)+TNFα(+)+IFNγ(+)D37[N=39;20] |
|
| CD4.CD40L(-)+IL-2(+)+TNFα(+)+IFNγ(+)D60[N=38;20] |
|
| CD4.CD40L(-)+IL-2(+)+TNFα(+)+IFNγ(+)D210[N=37;20] |
|
| CD4.CD40L(+)+IL-2(+)+TNFα(+)+IFNγ(+)D0[N=38;19] |
|
| CD4.CD40L(+)+IL-2(+)+TNFα(+)+IFNγ(+)D7[N=36;15] |
|
| CD4.CD40L(+)+IL-2(+)+TNFα(+)+IFNγ(+)D30[N=39;20] |
|
| CD4.CD40L(+)+IL-2(+)+TNFα(+)+IFNγ(+)D37[N=39;20] |
|
| CD4.CD40L(+)+IL-2(+)+TNFα(+)+IFNγ(+)D60[N=38;20] |
|
| CD4.CD40L(+)+IL-2(+)+TNFα(+)+IFNγ(+)D210[N=37;20] |
|
| CD8.CD40L(+)+IL-2(-)+TNFα(-)+IFNγ(-)D30[N=39;20] |
|
| CD8.CD40L(+)+IL-2(-)+TNFα(-)+IFNγ(-)D37[N=39;20] |
|
| CD8.CD40L(+)+IL-2(-)+TNFα(-)+IFNγ(-)D60[N=38;20] |
|
| CD8.CD40L(+)+IL-2(-)+TNFα(-)+IFNγ(-)D210[N=37;20] |
|
| CD8.CD40L(-)+IL-2(+)+TNFα(-)+IFNγ(-)D0[N=38;19] |
|
| CD8.CD40L(-)+IL-2(+)+TNFα(-)+IFNγ(-)D7[N=36;15] |
|
| CD8.CD40L(-)+IL-2(+)+TNFα(-)+IFNγ(-)D30[N=39;20] |
|
| CD8.CD40L(-)+IL-2(+)+TNFα(-)+IFNγ(-)D37[N=39;20] |
|
| CD8.CD40L(-)+IL-2(+)+TNFα(-)+IFNγ(-)D60[N=38;20] |
|
| CD8.CD40L(-)+IL-2(+)+TNFα(-)+IFNγ(-)D210[N=37;20] |
|
| CD8.CD40L(-)+IL-2(-)+TNFα(+)+IFNγ(-)D0[N=38;19] |
|
| CD8.CD40L(-)+IL-2(-)+TNFα(+)+IFNγ(-)D7[N=36;15] |
|
| CD8.CD40L(-)+IL-2(-)+TNFα(+)+IFNγ(-)D30[N=39;20] |
|
| CD8.CD40L(-)+IL-2(-)+TNFα(+)+IFNγ(-)D37[N=39;20] |
|
| CD8.CD40L(-)+IL-2(-)+TNFα(+)+IFNγ(-)D60[N=38;20] |
|
| CD8.CD40L(-)+IL-2(-)+TNFα(+)+IFNγ(-)D210[N=37;20] |
|
| CD8.CD40L(-)+IL-2(-)+TNFα(-)+IFNγ(+)D0[N=38;19] |
|
| CD8.CD40L(-)+IL-2(-)+TNFα(-)+IFNγ(+)D7[N=36;15] |
|
| CD8.CD40L(-)+IL-2(-)+TNFα(-)+IFNγ(+)D30[N=39;20] |
|
| CD8.CD40L(-)+IL-2(-)+TNFα(-)+IFNγ(+)D37[N=39;20] |
|
| CD8.CD40L(-)+IL-2(-)+TNFα(-)+IFNγ(+)D60[N=38;20] |
|
| CD8.CD40L(-)+IL-2(-)+TNFα(-)+IFNγ(+)D210[N=37;20] |
|
| CD8.CD40L(+)+IL-2(+)+TNFα(-)+IFNγ(-)D0[N=38;19] |
|
| CD8.CD40L(+)+IL-2(+)+TNFα(-)+IFNγ(-)D7[N=36;15] |
|
| CD8.CD40L(+)+IL-2(+)+TNFα(-)+IFNγ(-)D30[N=39;20] |
|
| CD8.CD40L(+)+IL-2(+)+TNFα(-)+IFNγ(-)D37[N=39;20] |
|
| CD8.CD40L(+)+IL-2(+)+TNFα(-)+IFNγ(-)D60[N=38;20] |
|
| CD8.CD40L(+)+IL-2(+)+TNFα(-)+IFNγ(-)D210[N=37;20] |
|
| CD8.CD40L(+)+IL-2(-)+TNFα(+)+IFNγ(-)D0[N=38;19] |
|
| CD8.CD40L(+)+IL-2(-)+TNFα(+)+IFNγ(-)D7[N=36;15] |
|
| CD8.CD40L(+)+IL-2(-)+TNFα(+)+IFNγ(-)D30[N=39;20] |
|
| CD8.CD40L(+)+IL-2(-)+TNFα(+)+IFNγ(-)D37[N=39;20] |
|
| CD8.CD40L(+)+IL-2(-)+TNFα(+)+IFNγ(-)D60[N=38;20] |
|
| CD8.CD40L(+)+IL-2(-)+TNFα(+)+IFNγ(-)D210[N=37;20] |
|
| CD8.CD40L(+)+IL-2(-)+TNFα(-)+IFNγ(+)D0[N=38;19] |
|
| CD8.CD40L(+)+IL-2(-)+TNFα(-)+IFNγ(+)D7[N=36;15] |
|
| CD8.CD40L(+)+IL-2(-)+TNFα(-)+IFNγ(+)D30[N=39;20] |
|
| CD8.CD40L(+)+IL-2(-)+TNFα(-)+IFNγ(+)D37[N=39;20] |
|
| CD8.CD40L(+)+IL-2(-)+TNFα(-)+IFNγ(+)D60[N=38;20] |
|
| CD8.CD40L(+)+IL-2(-)+TNFα(-)+IFNγ(+)D210[N=37;20] |
|
| CD8.CD40L(-)+IL-2(+)+TNFα(+)+IFNγ(-)D30[N=39;20] |
|
| CD8.CD40L(-)+IL-2(+)+TNFα(+)+IFNγ(-)D37[N=39;20] |
|
| CD8.CD40L(-)+IL-2(+)+TNFα(+)+IFNγ(-)D60[N=38;20] |
|
| CD8.CD40L(-)+IL-2(+)+TNFα(+)+IFNγ(-)D210[N=37;20] |
|
| CD8.CD40L(-)+IL-2(+)+TNFα(-)+IFNγ(+)D0[N=38;19] |
|
| CD8.CD40L(-)+IL-2(+)+TNFα(-)+IFNγ(+)D7[N=36;15] |
|
| CD8.CD40L(-)+IL-2(+)+TNFα(-)+IFNγ(+)D30[N=39;20] |
|
| CD8.CD40L(-)+IL-2(+)+TNFα(-)+IFNγ(+)D37[N=39;20] |
|
| CD8.CD40L(-)+IL-2(+)+TNFα(-)+IFNγ(+)D60[N=38;20] |
|
| CD8.CD40L(-)+IL-2(+)+TNFα(-)+IFNγ(+)D210[N=37;20] |
|
| CD8.CD40L(-)+IL-2(-)+TNFα(+)+IFNγ(+)D0[N=38;19] |
|
| CD8.CD40L(-)+IL-2(-)+TNFα(+)+IFNγ(+)D7[N=36;15] |
|
| CD8.CD40L(-)+IL-2(-)+TNFα(+)+IFNγ(+)D30[N=39;20] |
|
| CD8.CD40L(-)+IL-2(-)+TNFα(+)+IFNγ(+)D37[N=39;20] |
|
| CD8.CD40L(-)+IL-2(-)+TNFα(+)+IFNγ(+)D60[N=38;20] |
|
| CD8.CD40L(-)+IL-2(-)+TNFα(+)+IFNγ(+)D210[N=37;20] |
|
| CD8.CD40L(+)+IL-2(+)+TNFα(+)+IFNγ(-)D0[N=38;19] |
|
| CD8.CD40L(+)+IL-2(+)+TNFα(+)+IFNγ(-)D7[N=36;15] |
|
| CD8.CD40L(+)+IL-2(+)+TNFα(+)+IFNγ(-)D30[N=39;20] |
|
| CD8.CD40L(+)+IL-2(+)+TNFα(+)+IFNγ(-)D37[N=39;20] |
|
| CD8.CD40L(+)+IL-2(+)+TNFα(+)+IFNγ(-)D60[N=38;20] |
|
| CD8.CD40L(+)+IL-2(+)+TNFα(+)+IFNγ(-)D210[N=37;20] |
|
| CD8.CD40L(+)+IL-2(+)+TNFα(-)+IFNγ(+)D0[N=38;19] |
|
| CD8.CD40L(+)+IL-2(+)+TNFα(-)+IFNγ(+)D7[N=36;15] |
|
| CD8.CD40L(+)+IL-2(+)+TNFα(-)+IFNγ(+)D30[N=39;20] |
|
| CD8.CD40L(+)+IL-2(+)+TNFα(-)+IFNγ(+)D37[N=39;20] |
|
| CD8.CD40L(+)+IL-2(+)+TNFα(-)+IFNγ(+)D60[N=38;20] |
|
| CD8.CD40L(+)+IL-2(+)+TNFα(-)+IFNγ(+)D210[N=37;20] |
|
| CD8.CD40L(+)+IL-2(-)+TNFα(+)+IFNγ(+)D0[N=38;19] |
|
| CD8.CD40L(+)+IL-2(-)+TNFα(+)+IFNγ(+)D7[N=36;15] |
|
| CD8.CD40L(+)+IL-2(-)+TNFα(+)+IFNγ(+)D30[N=39;20] |
|
| CD8.CD40L(+)+IL-2(-)+TNFα(+)+IFNγ(+)D37[N=39;20] |
|
| CD8.CD40L(+)+IL-2(-)+TNFα(+)+IFNγ(+)D60[N=38;20] |
|
| CD8.CD40L(+)+IL-2(-)+TNFα(+)+IFNγ(+)D210[N=37;20] |
|
| CD8.CD40L(-)+IL-2(+)+TNFα(+)+IFNγ(+)D0[N=38;19] |
|
| CD8.CD40L(-)+IL-2(+)+TNFα(+)+IFNγ(+)D7[N=36;15] |
|
| CD8.CD40L(-)+IL-2(+)+TNFα(+)+IFNγ(+)D30[N=39;20] |
|
| CD8.CD40L(-)+IL-2(+)+TNFα(+)+IFNγ(+)D37[N=39;20] |
|
| CD8.CD40L(-)+IL-2(+)+TNFα(+)+IFNγ(+)D60[N=38;20] |
|
| CD8.CD40L(-)+IL-2(+)+TNFα(+)+IFNγ(+)D210[N=37;20] |
|
| CD8.CD40L(+)+IL-2(+)+TNFα(+)+IFNγ(+)D0[N=38;19] |
|
| CD8.CD40L(+)+IL-2(+)+TNFα(+)+IFNγ(+)D7[N=36;15] |
|
| CD8.CD40L(+)+IL-2(+)+TNFα(+)+IFNγ(+)D30[N=39;20] |
|
| CD8.CD40L(+)+IL-2(+)+TNFα(+)+IFNγ(+)D37[N=39;20] |
|
| CD8.CD40L(+)+IL-2(+)+TNFα(+)+IFNγ(+)D60[N=38;20] |
|
| CD8.CD40L(+)+IL-2(+)+TNFα(+)+IFNγ(+)D210[N=37;20] |
|
| Anti-M72, D60 |
|
| Anti-M72, D210 |
|